Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2023 / Sep / Retinal Flow
Retina Research & Innovations

Retinal Flow

Researchers develop an innovative technique for retinal imaging that could predict chronic cerebral hypoperfusion

By Alun Evans 9/12/2023 2 min read

Share

Chronic cerebral hypoperfusion (CCH) can be caused by several conditions that affect the cerebral vascular system, including diabetes, hypertension, and atherosclerosis – but lifestyle choices, such as smoking, also play a role. With CCH now recognized as a key contributor to the neurodegenerative processes that can lead to dementia (1), attention has turned to early diagnosis and prediction. And a new study (2) has proposed that retinal imaging – or, more precisely, exploring the retinal microvasculature using two-photon microscopy – shows potential in predicting the risk of brain diseases involving reduced blood flow.

Two-photon microscopy is a fluorescence-based technique that can be used to measure living tissue with approximately one millimeter thickness. The novel imaging technique - innovative in that it requires no adaptive optics – allows researchers to investigate retinal blood flow at the microscopic level. Because the retina is located in the peripheral part of the central nervous system – sharing similarities with cerebral brain matter but with a simpler structure and fewer nerve cell types – it makes it an excellent target for providing more accurate insights into the microvasculature of the brain. The study findings suggest this new technique has the potential to be applied to a wide variety of retinal research, and serve as a promising predictor for CCH, as well as acting as an early diagnostic biomarker for other cerebrovascular diseases.

References

  1. J Duncombe et al., “Chronic cerebral hypoperfusion: a key mechanism leading to vascular cognitive impairment and dementia. Closing the translational gap between rodent models and human vascular cognitive impairment and dementia,” Clinical Science, 131, 2451 (2017). PMID: 28963120.
  2. L Baoqiang et al., “Differential reductions in the capillary red-blood-cell flux between retina and brain under chronic global hypoperfusion,” Neurophotonics, [Online ahead of print] (2023). PMID: 37323511.

About the Author(s)

Alun Evans

More Articles by Alun Evans

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: